CROI 2018 Abstract eBook

Abstract eBook

Keyword Index

p38 MAPK 20 Partner services 977, 1024 Partner testing 977, 992

Prisoners 96, 1133 Probiotic 257, 274, 419 Prophylaxis 490, 799 Protease inhibitors 123, 269, 493, 558, 559, 805, 836 Protein kinase C agonist 324

Scale-up 90, 1053, 1113 sCD14 313 sCD163 860 Schizophrenia 894 Screening 291, 404, 563, 576, 577, 579, 715, 772, 1000, 1014, 1075 Self-report 910, 912, 1000 Self-testing 150LB, 992, 995, 996 Semen 250, 478 SERINC5 116, 201, 202 Seroconversion 565, 998, 1038 Serodiscordant couples 1085 Severe immunodeficiency 23, 490, 531, 896 Sex work 922, 1045 Sexual function 1073 Sexual partners 148, 923 Sexual risk behavior 148, 593, 905, 909, 915, 926, 1025 Sexual transmission 588, 593 Sexual violence 922 Sexually transmitted infection 625, 915, 978, 980, 1014, 1024, 1025, 1026, 1027, 1075 SHIV 167, 207, 351, 476, 82, 89LB Short cycle therapy 507 Signaling 282, 417

Passive immunoprophylaxis 827 Pathogenesis 17, 19, 169, 215, 882 Pattern recognition receptor 321 PD-1 155, 316, 363, 371, 656LB Pediatric HIV 32, 290, 487, 822, 824, 825, 843, 844, 866 Pediatric HIV vaccine 871 People who inject drugs 1101LB, 1107, 1158, 205, 44, 587, 589, 605, 629, 888, 929, 962, 964, 967, 971 Perinatal HIV infection 388, 702, 846, 847, 867, 877, 882 Peripheral arterial disease 76, 701, 856 Peripheral blood mononuclear cells (PBMCs) 285, 318 Peripheral immune activation 449 Perivascular adipose tissue 680 Permissive cells 240 Persistence 1010, 1028, 119, 374LB, 376, 393, 66, 70, 790 PET imaging 345, 426, 429, 438, 440, 441LB PF-68742 112 Pharmacologic measures 463 Pharmacovigilance 462, 494 Phenotypic resistance 547 Phylodynamics 42, 372, 584, 945, 946, 949, 953 Phylogenetic clustering 169, 626, 945, 948, 950, 952 Phylogenetics 41, 42, 130, 288, 344, 372, 938, 944, 946, 949, 950, 951, 952, 960 Phylogeography 43, 582, 945, 951, 954 Placenta 810, 834 Platelets 251LB, 673, 677LB, 80 Pneumocystis 795 Point of care 557, 563, 564, 566 Pol 556 Population based 91, 336, 717, 822, 900, 916, 918, 1052, 1084 Population effectiveness 88 Postexposure prophylaxis PEP 592, 613, 962, 1032, 1033, 1037, 1050 Postpartum 45, 138, 337, 812, 820, 1088 Predictors 512, 609, 927, 1048, 1107 Preferences 1148 Pregancy outcome 805 Pregnancy 1147, 142LB, 267, 428, 45, 740, 804, 809, 820, 835, 836 Pregnancy intention 1071 Pregnancy outcome 803, 829, 832, 834 Pregnant and breastfeeding women 140, 721, 807, 817, 1047 Pregnant women 269, 806, 814, 876, 1047 Premature aging 758 PrEP 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022LB, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1031, 1032, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1059LB, 1060LB, 1070, 1087, 1146, 1149, 1150, 1151, 143LB, 203, 463, 481, 486, 562, 573, 585, 589, 590, 592, 613, 809, 82, 83, 85, 86, 87, 878, 88, 962, 982 • Continuum 982, 1005, 1013, 1030, 1038, 1087 • Discontinuation 1038 • Eligibility 1030, 1039, 1048 Preterm delivery 269, 830, 835, 836, 876, 879 Prevention 1009, 1014, 1018, 1027, 1038, 1042, 1045, 1049, 1060LB, 1065, 1097, 1156, 143LB, 37LB, 41, 768, 923 Phagocytosis 302, 454, 777 Pharmacodynamics 479 Pharmacogenetics 402, 466, 467 Pharmacokinetics 1061, 26, 27, 28LB, 34, 456, 457, 462, 465, 466, 467, 468, 470, 473, 479, 480, 487, 488, 781, 807, 810, 83, 841

Proteinuria 808, 850 Proteome 271, 1056 Proteomics 218, 267, 453

Proviral DNA 156, 340, 389, 535 Pulmonary disease 714, 747, 748 Quantification 575 QVOA 156, 388, 396, 397, 398 R5X4 183

Race/Racial differences 86, 205, 903, 906, 914, 939, 957, 1045 Raltegravir 23, 190, 314, 470, 496, 531, 776, 805, 806, 845 Randomized controlled trial 1062, 1106, 142LB, 23, 24, 313, 38LB, 39LB, 490, 516, 531, 703, 769, 784, 807, 819, 859, 885LB, 96 Randomized open-label trial 29LB, 723, 94 Randomized trial 24, 507, 1106 Re-admission 696, 697, 902 Reactivation 203, 325 Reactive oxygen species 680 Rebound virus 124, 336, 338, 377 Recency of HIV infection 927, 1002, 1003 Recombinants 168, 188, 540, 566 Rectal 89LB, 980 Renal impairment 728, 808 Repertoire 295 Replication 167, 704 Replication-competent reservoir 68, 362, 366, 378 Reproductive health 1069 Reproductive tract infections 1075 Reservoir 119, 124, 152LB, 155, 157, 325, 334, 335, 342, 348, 349, 350, 363, 364, 367, 368, 369, 370, 372, 374LB, 376, 378, 379, 391, 392, 393, 397, 403LB, 446, 447, 475, 476, 67, 70, 71, 73LB, 865 Resident memory T cells 367 Residual viremia 71, 323, 341, 370 Resistance 506, 514, 526, 530, 531, 532, 541 • Associated variants 583, 938 • Mutation 123, 536, 546, 583, 529 Resource allocation and workloads 1076 Resource limited settings 1130, 1142, 30LB, 409, 771, 819 Restriction factor 182LB, 191LB, 196 Retention 756, 854, 884, 898, 1081, 1103 Retention in care 1010, 1013, 1044, 1086, 1088, 1091, 1095, 1099, 1102, 1103, 1105, 1110, 1111LB, 1128, 1132, 1140, 526, 756, 817, 818, 892 Rhesus macaque 253, 348, 377 Rifabutin 781 Rifampicin 456, 457, 458, 838 • Biopsies 383 • Infection 906 • Microbicides 1058, 1060LB

Simian foamy virus 174 SIMOA p24 assay 388, 396 Simulation 507, 1151 Simulation modeling 1157 Single cell 442

Single cell analysis 326 Single copy assay 574 Single genome sequencing 359, 372 Single viral suppression 940 Single-tablet regimen 492, 499, 502, 844, 1079 Single-virus detection 185

SIV 117, 124, 167, 17, 190, 210, 221, 235, 241, 266, 273, 276, 282, 287, 345, 349, 350, 375, 376, 377, 421, 426, 429, 441LB, 452 Sleep apnea 697 Smoking 242, 746, 747, 750, 897 SNP 206 Social determinants of health 915, 1134 Social media 916, 1016

Social network 964 Social norms 1065 Soluble biomarkers 238 SOSIPs 16LB

South Africa 1070, 1079, 1088, 1089, 1106, 1111LB, 1138, 1153, 140, 149, 522, 551, 650, 661, 715, 779, 786, 814, 861, 924, 925, 934, 987, 990, 992 Spatial analysis 779, 954, 1006

Spinal cord 124 Spirometry 750 Splicing 114, 115, 153 Spontaneous clearance 640 State sequence data analysis 1138

Keyword Index

Rifampin 28LB, 34, 39LB Rifapentine 37LB, 455 Rifaximin 313

Statins 132, 689, 690, 705 STD clinic 982, 1033, 1108 Steatosis 643 Stem cell transplantation 318, 386 Stigma 1128 Stillbirth 803, 830, 834 Stimulant use 1031 Stress 420 Structure 191LB, 194, 294 Sub-Saharan Africa 407, 530, 566, 710, 716, 752, 899, 1071, 1082 Subclinical atherosclerosis 670 Subcutaneous Fat 685, 734 Subgroups 491 Substance use 181, 265, 753, 975, 1035, 1078, 1097 Subtype 226, 405 Subtype C 339, 451, 950

Rilpivirine 458, 485, 504, 562 Risk compensation 1025, 1054 Risk factors 404, , 544, 692, 714, 795, 896, 922, 924, 928 Risk prediction 205 Risk score 730, 924, 1021, 1075

RNA 115, 191LB, 194, 391, 572, 575, 585 RNA seq 117, 153, 214, 330, 442, 868 RNA-Protein Interaction 191LB Romidepsin 72, 359 RV144 300, 307 Ryan white program 1109, 1134 S230R mutation 548 Safety 1059LB, 142LB, 494 SAMHD1 189 Sarcopenia 755

Primary care 594, 599, 705, 1011, 1028 Primary HIV infection 120, 272, 529, 946 Primary HIV-1 isolates 549

CROI 2018 482